Semaglutide (GLP-1) — Medical Weight Loss at RegenesisMD
Physician-supervised GLP-1 receptor agonist therapy for medically guided weight management. Semaglutide is an FDA-approved GLP-1 (glucagon-like peptide-1) receptor agonist. While it has FDA approval for type 2 diabetes management and chronic weight management (as Wegovy®), RegenesisMD prescribes compounded semaglutide, which is not FDA-approved. The FDA has not evaluated the safety or effectiveness of compounded semaglutide. Pricing: $400–$600/month. Typical program: 4–12 weeks initial, ongoing weekly injection.
How semaglutide works
Regulates appetite signals in the brain.
Slows gastric emptying, promoting satiety.
Supports blood glucose regulation.
Influences metabolic pathways.
FDA-approved semaglutide (Wegovy®) clinical trials showed participants lost an average of 12.4% of initial body weight over 68 weeks, in combination with a reduced-calorie diet and increased physical activity. Individual results varied widely; not all participants achieved significant weight loss. Compounded semaglutide may differ in efficacy, safety, and outcomes.
Who may be a candidate
BMI ≥27 with weight-related health concerns, or BMI ≥30.
Have struggled with traditional diet and exercise approaches.
Committed to lifestyle modifications alongside medication.
Metabolic health concerns such as insulin resistance or pre-diabetes.
Contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy or nursing, type 1 diabetes, severe gastrointestinal disease, and other conditions determined by your physician.
Safety information
Common side effects: nausea, vomiting, diarrhea (usually mild and temporary); constipation; abdominal discomfort; fatigue; headache; injection site reactions.
Serious risks: thyroid C-cell tumors (see black box warning), pancreatitis, gallbladder problems, kidney problems, diabetic retinopathy complications, allergic reactions. You must discuss all risks and benefits with a RegenesisMD provider before starting treatment.
Protocol
Comprehensive medical evaluation and lab work.
Individualized dosing protocol.
Regular monitoring and follow-up appointments.
Nutritional guidance and lifestyle support.
Side effect management.
Maintenance planning.
Frequently Asked Questions
How much weight can I lose with Semaglutide?
FDA-approved semaglutide (Wegovy®) clinical trials showed participants lost an average of 12.4% of initial body weight over 68 weeks. Results were achieved in combination with a reduced-calorie diet and increased physical activity. Individual results varied widely — not all participants achieved significant weight loss. These results are from FDA-approved formulations studied in clinical trials. Compounded semaglutide may differ in efficacy, safety, and outcomes.
What are the side effects?
Common side effects may include nausea, vomiting, and diarrhea (usually mild and temporary), constipation, abdominal discomfort, fatigue, headache, and injection site reactions. Serious risks include thyroid C-cell tumors (see black box warning), pancreatitis, gallbladder problems, kidney problems, diabetic retinopathy complications, and allergic reactions. You must discuss all risks and benefits with one of our RegenesisMD providers before starting treatment.
Is Semaglutide FDA approved?
Semaglutide is FDA-approved for chronic weight management and type 2 diabetes under brand names Wegovy® and Ozempic®. However, we prescribe compounded semaglutide, which is not FDA-approved. The FDA has not evaluated the safety or effectiveness of compounded semaglutide.
Medical disclaimer
This page is educational and does not constitute medical advice. Compounded semaglutide is not FDA-approved and is not represented as clinically equivalent to brand-name FDA-approved formulations. Individual results vary; outcomes are not guaranteed. Treatment requires an in-person physician evaluation, lab work, and ongoing monitoring.